Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $410
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $390 to $410.
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $390 to $410.